AES 2022 | Predictors of maintained response to cenobamate in patients with epilepsy

Sean Stern, MS, SK Life Science, Inc., shares the findings of a post-hoc analysis assessing predictors of sustainability of response to cenobamate therapy. A total of 214 patients from the C021 Phase III open-label safety study of cenobamate (NCT02535091) were included in the analysis, all of whom had a ≥ 50% or 100% seizure reduction response for ≥ 3 months. Clinical characteristics found to be associated with maintenance of response included concomitant drug load and duration of epilepsy. Lower baseline drug load and shorter duration of epilepsy were associated with longer times to first loss of ≥ 50% seizure reduction. Lower baseline drug load and seizure frequency were associated with longer times to first and fourth loss of 100% seizure reduction. This interview took place at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, TN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.